Bavarian Nordic JYNNEOS is the only U.S. FDA approved non-replicating smallpox and monkeypox vaccine JYNNEOS Smallpox Vaccine
Denmark (Precision Vaccinations)
The U.S. Biomedical Advanced Research and Development Authority (BARDA) has exercised the final $12 million option for JYNNEOS, an innovative combination of Smallpox and Monkeypox vaccine.
JYNNEOS is the only U.S. Food and Drug Administration-approved non-replicating smallpox and monkeypox vaccine for preventing disease in adults 18 years of age and older.
Initially awarded in April 2020, this option covers the supply of additional liquid-frozen JYNNEOS doses manufactured in Denmark-based Bavarian Nordic A/S’s new fill and finish facility 2021.
The JYNNEOS vaccine is based on a live, attenuated vaccinia virus (Modified Vaccinia Ankara, MVA-BN), incapable of replicating in the body, yet still capable of eliciting a potent immune response.
Share:
COPENHAGEN, Denmark, May 7, 2021 – Bavarian Nordic A/S ((OMX: BAVA, OTC:BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the final USD 12 million option remaining under the USD 202 million order for JYNNEOS
® (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.
This option covers the supply of additional liquid-frozen JYNNEOS doses which will be manufactured in the Company s new fill and finish facility during 2021. In addition, the total contract of USD 202 million for procurement includes manufacturing of bulk vaccine, which is revenue recognized in the years 2020-2022.
(0)
COPENHAGEN, Denmark, May 7, 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the final USD 12 million option remaining under the USD 202 million order for JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.
This option covers the supply of additional liquid-frozen JYNNEOS doses which will be manufactured in the Company s new fill and finish facility during 2021. In addition, the total contract of USD 202 million for procurement includes manufacturing of bulk vaccine, which is revenue recognized in the years 2020-2022.
Danish
COPENHAGEN, Denmark, May 7, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the final USD 12 million option remaining under the USD 202 million order for JYNNEOS
® (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.
This option covers the supply of additional liquid-frozen JYNNEOS doses which will be manufactured in the Company’s new fill and finish facility during 2021. In addition, the total contract of USD 202 million for procurement includes manufacturing of bulk vaccine, which is revenue recognized in the years 2020-2022.
(1)
COPENHAGEN, Denmark, April 29, 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today reported additional preclinical data for the capsid virus-like particle (cVLP) COVID-19 vaccine candidate, ABNCoV2, confirming its ability to induce neutralizing antibodies against SARS-CoV-2 variants.
Bavarian Nordic previously reported preclinical data, showing that two doses of non-adjuvanted ABNCoV2 led to >50-fold higher titers of neutralizing antibodies against the wild-type (Wuhan) virus when compared to titers measured in convalescent human samples, and this translated into protection from a challenge with wild-type virus. A neutralization test of samples from the study has now confirmed similarly high levels of neutralizing antibodies against the SARS-CoV2 variants B.1.1.7 (British) and B.1.351 (South African). These are highly encouraging results as it has been reported that high levels of neutralizing antibodies are highly predictive of protection (Khoury et al. doi.org/10.1101/2